In 1978, Kiran Mazumdar-Shaw started Biocon in a rented garage in Bangalore with a seed capital of Rs 10,000 and a conviction that India could do more than manufacture other people’s molecules. Forty-five years later, Biocon is a $1.95 billion biopharmaceutical enterprise and the world’s leading manufacturer of biosimilar insulins — a trajectory that rewrote assumptions about what an Indian company could achieve in biologics.
Biosimilars are to biologics what generics are to small-molecule drugs — except that the science is orders of magnitude harder. A generic tablet is a chemical copy. A biosimilar is a living system: manufactured in cell cultures, folded into three-dimensional proteins, and subject to the kind of molecular complexity that makes exact replication impossible. The regulatory bar is correspondingly higher. This is why, two decades after the first biosimilar approvals, the number of companies with genuine end-to-end biosimilar capability remains small.
Biocon is one of them. Through its subsidiary Biocon Biologics, the company has built a portfolio spanning insulin analogues, oncology monoclonal antibodies, and immunology biosimilars. In FY 2025, biosimilars accounted for 58% of consolidated revenue — more than $1.1 billion. This is not a generics company that added a biosimilar division. Biosimilars are the company.
The insulin franchise alone is globally significant. Biocon manufactures biosimilar insulin glargine, insulin aspart, and insulin lispro at a scale that serves millions of patients in more than 100 countries. For diabetic patients in emerging markets where the originator biologics are prohibitively expensive, Biocon’s biosimilar insulins are often the only affordable option. The clinical need and the commercial opportunity are the same thing.
Biocon operates across four integrated verticals. Biosimilars (58% of FY 2025 revenue) is the growth engine, with products commercialised in the US, EU, and more than 100 emerging markets. Research Services (23%), operated through listed subsidiary Syngene International, provides contract research and manufacturing to 14 of the world’s 20 largest pharmaceutical companies. Generics (19%) supplies APIs and finished dosage forms across cardiovascular, anti-diabetic, and immunosuppressant therapies. Novel Biologics, the fourth vertical, pursues proprietary molecule development.
The integration between these verticals is the structural advantage. Syngene’s research capabilities feed Biocon’s development pipeline. The generics API business provides chemistry expertise that supports biosimilar process development. The manufacturing infrastructure serves all four verticals. This is not a conglomerate of unrelated businesses — it is a vertically integrated biopharmaceutical platform where each piece makes the others stronger.
Biocon operates twelve manufacturing sites across six countries: India, the United States, Brazil, Malaysia, the Philippines, and Switzerland. This is not a typical Indian pharma footprint. The Malaysian facility produces biosimilar insulins at global scale. The US operations support the American biosimilar market. The Brazilian and Philippine sites serve Latin American and ASEAN demand with locally manufactured product. Switzerland provides the regulatory credibility and API capabilities that the European market requires.
The geographic distribution reflects a deliberate strategy: manufacture where you sell, not just where it is cheapest. For biosimilars, where cold-chain logistics and regulatory compliance are critical, proximity to the end market is a competitive advantage that pure cost arbitrage cannot replicate.
Sources: Biocon Integrated Annual Reports FY2020–21 through FY2024–25. US FDA facility registration data. Indian patent office records.